2026 Q2 - tulosraportti
27 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 | - | - | ||
| 1 293 | - | - | ||
| 1 073 | - | - | ||
| 1 885 | - | - | ||
| 212 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·10 t sittenA thought I had after reading about Moderna/Merck and INTerpath-001: I was reading the discussions about Moderna/Merck here and on other forums, and started thinking about one thing: What if a personalized cancer vaccine isn't just made once? Cancer doesn't stand still. Some cancer cells die, others survive, and the tumor can change along the way. Then it actually makes sense that the treatment must also be able to change. In practice, it could look something like this: One maps the tumor, finds the neoantigens one wants to attack and creates the vaccine. Then one follows the patient with, for example, ctDNA/MRD and possibly new samples. If the cancer changes and other clones take over, one performs a new analysis, chooses new targets and creates an updated vaccine. So not just: one patient and one vaccine, but perhaps eventually: one patient who receives their excellent Nykode vaccine. Nykode monitors the development, and then updates the vaccine. This is where I find Nykode interesting. NeoSELECT is to find which neoantigens are most sensible to target, and VB10.NEO is built based on these choices. Nykode has simultaneously reduced production time to under 6 weeks. During Q&A in August, they also said that around 4 weeks would be possible if production is gathered under one roof and staffing is available through weekends. And that's when production time starts to mean a lot more. If it takes five months to make the next vaccine, the cancer might be in a completely different place when it's ready. If you can do it in just four weeks, this starts to become something else! What I'm wondering, therefore, is whether NeoSELECT/VB10.NEO can in principle be used repeatedly during the course of the disease, so that one updates which neoantigens are targeted as the tumor changes? This is not something I've seen Nykode say they will do. It's just a thought about where the field might be heading. But if personalized cancer treatment eventually becomes more continuous and less "make one vaccine and done", I believe both NeoSELECT, AI and rapid production will become even more important. Exciting times, guys!
Very interesting observations you are making. I am by no means an expert on cancer vaccines, but I have enough insight into what you are talking about to understand what it's all about. However, I am quite good at steak and almost an expert on complex red wines, so for many reasons, I look forward to Nykode succeeding.
·12 t sittenRetrieved from Xtrainvestor: "Moderna has received LBA1 (Late-Breaking Abstract 1) for INTerpath-001 at ESMO 2026. The presentation has been added to the Presidential Symposium on Saturday, October 24th at 16:30 CEST in Madrid, presented by Georgina Long. Moderna will then hold its own webcast at 19:00 CEST the same evening. This is more important than an ordinary poster/oral presentation. That INTerpath-001 is LBA1 in the Presidential Symposium is a strong signal that ESMO considers the dataset to be one of the congress's most significant late-breaking results. It also aligns with Merck/Moderna's previous information that the study, already at the pre-specified interim analysis, showed both statistically significant and clinically meaningful improvement in RFS and DMFS. For Nykode and VB10.NEO, this could make the partner discussion significantly more attractive: a potential partner no longer needs to first believe whether individualized neoantigens can work. Merck/Moderna will then have proven the concept in a large Phase 3 study. The competition is largely shifting to who can deliver the best antigen selection, immune response, production time, cost, and scalability. It is precisely there that Nykode must document that VB10.NEO/the platform has competitive advantages. For example, Merck/Moderna is at 6 weeks production time and Nykode is at just under 6 weeks and has the ambition to get down to 4 weeks 🙏"
·23 t sittenIt looks like the analyses Nordnet shares are not worth much. It's a bit random whose analyses get to be included. Take for example NYKD and TRMED. There are a couple more that cover NYKD, but only one is shown and one of those not included is mentioned in TRMED🧐
23 t sittenJust been reading the unicorn project, in it it references crossing the chasm by Geoffrey A. Moore, who says that in biotech the first one to market for a particular therapy type can expect to get 50% of the market share, the second to market will get around 25% the third even less and anyone else may have wasted their money on r and d. This is the first time i have come across this, is there any truth to this?21 t sittenNever mind. Googled it, it's a real thing, possibly doesn't apply too much to nykode in the strict sense. Nice to learn something new 🙂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
27 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenA thought I had after reading about Moderna/Merck and INTerpath-001: I was reading the discussions about Moderna/Merck here and on other forums, and started thinking about one thing: What if a personalized cancer vaccine isn't just made once? Cancer doesn't stand still. Some cancer cells die, others survive, and the tumor can change along the way. Then it actually makes sense that the treatment must also be able to change. In practice, it could look something like this: One maps the tumor, finds the neoantigens one wants to attack and creates the vaccine. Then one follows the patient with, for example, ctDNA/MRD and possibly new samples. If the cancer changes and other clones take over, one performs a new analysis, chooses new targets and creates an updated vaccine. So not just: one patient and one vaccine, but perhaps eventually: one patient who receives their excellent Nykode vaccine. Nykode monitors the development, and then updates the vaccine. This is where I find Nykode interesting. NeoSELECT is to find which neoantigens are most sensible to target, and VB10.NEO is built based on these choices. Nykode has simultaneously reduced production time to under 6 weeks. During Q&A in August, they also said that around 4 weeks would be possible if production is gathered under one roof and staffing is available through weekends. And that's when production time starts to mean a lot more. If it takes five months to make the next vaccine, the cancer might be in a completely different place when it's ready. If you can do it in just four weeks, this starts to become something else! What I'm wondering, therefore, is whether NeoSELECT/VB10.NEO can in principle be used repeatedly during the course of the disease, so that one updates which neoantigens are targeted as the tumor changes? This is not something I've seen Nykode say they will do. It's just a thought about where the field might be heading. But if personalized cancer treatment eventually becomes more continuous and less "make one vaccine and done", I believe both NeoSELECT, AI and rapid production will become even more important. Exciting times, guys!Very interesting observations you are making. I am by no means an expert on cancer vaccines, but I have enough insight into what you are talking about to understand what it's all about. However, I am quite good at steak and almost an expert on complex red wines, so for many reasons, I look forward to Nykode succeeding.
- ·12 t sittenRetrieved from Xtrainvestor: "Moderna has received LBA1 (Late-Breaking Abstract 1) for INTerpath-001 at ESMO 2026. The presentation has been added to the Presidential Symposium on Saturday, October 24th at 16:30 CEST in Madrid, presented by Georgina Long. Moderna will then hold its own webcast at 19:00 CEST the same evening. This is more important than an ordinary poster/oral presentation. That INTerpath-001 is LBA1 in the Presidential Symposium is a strong signal that ESMO considers the dataset to be one of the congress's most significant late-breaking results. It also aligns with Merck/Moderna's previous information that the study, already at the pre-specified interim analysis, showed both statistically significant and clinically meaningful improvement in RFS and DMFS. For Nykode and VB10.NEO, this could make the partner discussion significantly more attractive: a potential partner no longer needs to first believe whether individualized neoantigens can work. Merck/Moderna will then have proven the concept in a large Phase 3 study. The competition is largely shifting to who can deliver the best antigen selection, immune response, production time, cost, and scalability. It is precisely there that Nykode must document that VB10.NEO/the platform has competitive advantages. For example, Merck/Moderna is at 6 weeks production time and Nykode is at just under 6 weeks and has the ambition to get down to 4 weeks 🙏"
- ·23 t sittenIt looks like the analyses Nordnet shares are not worth much. It's a bit random whose analyses get to be included. Take for example NYKD and TRMED. There are a couple more that cover NYKD, but only one is shown and one of those not included is mentioned in TRMED🧐
- 23 t sittenJust been reading the unicorn project, in it it references crossing the chasm by Geoffrey A. Moore, who says that in biotech the first one to market for a particular therapy type can expect to get 50% of the market share, the second to market will get around 25% the third even less and anyone else may have wasted their money on r and d. This is the first time i have come across this, is there any truth to this?21 t sittenNever mind. Googled it, it's a real thing, possibly doesn't apply too much to nykode in the strict sense. Nice to learn something new 🙂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 | - | - | ||
| 1 293 | - | - | ||
| 1 073 | - | - | ||
| 1 885 | - | - | ||
| 212 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
27 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenA thought I had after reading about Moderna/Merck and INTerpath-001: I was reading the discussions about Moderna/Merck here and on other forums, and started thinking about one thing: What if a personalized cancer vaccine isn't just made once? Cancer doesn't stand still. Some cancer cells die, others survive, and the tumor can change along the way. Then it actually makes sense that the treatment must also be able to change. In practice, it could look something like this: One maps the tumor, finds the neoantigens one wants to attack and creates the vaccine. Then one follows the patient with, for example, ctDNA/MRD and possibly new samples. If the cancer changes and other clones take over, one performs a new analysis, chooses new targets and creates an updated vaccine. So not just: one patient and one vaccine, but perhaps eventually: one patient who receives their excellent Nykode vaccine. Nykode monitors the development, and then updates the vaccine. This is where I find Nykode interesting. NeoSELECT is to find which neoantigens are most sensible to target, and VB10.NEO is built based on these choices. Nykode has simultaneously reduced production time to under 6 weeks. During Q&A in August, they also said that around 4 weeks would be possible if production is gathered under one roof and staffing is available through weekends. And that's when production time starts to mean a lot more. If it takes five months to make the next vaccine, the cancer might be in a completely different place when it's ready. If you can do it in just four weeks, this starts to become something else! What I'm wondering, therefore, is whether NeoSELECT/VB10.NEO can in principle be used repeatedly during the course of the disease, so that one updates which neoantigens are targeted as the tumor changes? This is not something I've seen Nykode say they will do. It's just a thought about where the field might be heading. But if personalized cancer treatment eventually becomes more continuous and less "make one vaccine and done", I believe both NeoSELECT, AI and rapid production will become even more important. Exciting times, guys!Very interesting observations you are making. I am by no means an expert on cancer vaccines, but I have enough insight into what you are talking about to understand what it's all about. However, I am quite good at steak and almost an expert on complex red wines, so for many reasons, I look forward to Nykode succeeding.
- ·12 t sittenRetrieved from Xtrainvestor: "Moderna has received LBA1 (Late-Breaking Abstract 1) for INTerpath-001 at ESMO 2026. The presentation has been added to the Presidential Symposium on Saturday, October 24th at 16:30 CEST in Madrid, presented by Georgina Long. Moderna will then hold its own webcast at 19:00 CEST the same evening. This is more important than an ordinary poster/oral presentation. That INTerpath-001 is LBA1 in the Presidential Symposium is a strong signal that ESMO considers the dataset to be one of the congress's most significant late-breaking results. It also aligns with Merck/Moderna's previous information that the study, already at the pre-specified interim analysis, showed both statistically significant and clinically meaningful improvement in RFS and DMFS. For Nykode and VB10.NEO, this could make the partner discussion significantly more attractive: a potential partner no longer needs to first believe whether individualized neoantigens can work. Merck/Moderna will then have proven the concept in a large Phase 3 study. The competition is largely shifting to who can deliver the best antigen selection, immune response, production time, cost, and scalability. It is precisely there that Nykode must document that VB10.NEO/the platform has competitive advantages. For example, Merck/Moderna is at 6 weeks production time and Nykode is at just under 6 weeks and has the ambition to get down to 4 weeks 🙏"
- ·23 t sittenIt looks like the analyses Nordnet shares are not worth much. It's a bit random whose analyses get to be included. Take for example NYKD and TRMED. There are a couple more that cover NYKD, but only one is shown and one of those not included is mentioned in TRMED🧐
- 23 t sittenJust been reading the unicorn project, in it it references crossing the chasm by Geoffrey A. Moore, who says that in biotech the first one to market for a particular therapy type can expect to get 50% of the market share, the second to market will get around 25% the third even less and anyone else may have wasted their money on r and d. This is the first time i have come across this, is there any truth to this?21 t sittenNever mind. Googled it, it's a real thing, possibly doesn't apply too much to nykode in the strict sense. Nice to learn something new 🙂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 | - | - | ||
| 1 293 | - | - | ||
| 1 073 | - | - | ||
| 1 885 | - | - | ||
| 212 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt